Fact-checked by Grok 2 weeks ago

ICAM-1

Intercellular adhesion molecule 1 (ICAM-1), also known as CD54, is a transmembrane glycoprotein encoded by the ICAM1 gene located on human chromosome 19p13.2, belonging to the immunoglobulin superfamily of adhesion molecules. ICAM-1 was first identified in 1988 as a ligand for the leukocyte function-associated antigen 1 (LFA-1).^[1] It primarily functions to mediate cell-cell interactions by binding β2-integrins such as LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18) on leukocytes, thereby facilitating their adhesion to endothelial cells and transmigration during inflammatory responses.^[2]^[3]^[4] ICAM-1's structure features five extracellular immunoglobulin-like domains (D1–D5), a single transmembrane helix, and a short cytoplasmic tail of approximately 28 amino acids, resulting in a mature protein of 532 residues with a molecular weight ranging from 60 to 114 kDa due to N- and O-linked glycosylation; alternative splicing generates multiple isoforms, including a soluble form (sICAM-1) lacking the transmembrane and cytoplasmic domains.^[3]^[4] It is constitutively expressed at low levels on endothelial cells, epithelial cells, fibroblasts, and immune cells such as lymphocytes and monocytes, with highest expression in lung and bone marrow tissues, and can be rapidly upregulated on various cell types in response to proinflammatory stimuli.^[2]^[3]^[4] Beyond its canonical role in leukocyte-endothelial adhesion and immune cell trafficking, ICAM-1 serves as a costimulatory molecule in immune synapse formation, a receptor for pathogens including rhinoviruses and Plasmodium falciparum, and a regulator of intracellular signaling pathways involving Rho GTPases, Src kinases, and actin cytoskeleton reorganization, which influence processes like barrier function, efferocytosis, and wound healing.^[2]^[3]^[4] Its expression is tightly regulated by cytokines such as TNF-α, IL-1β, and IFN-γ through transcription factors like NF-κB, AP-1, and STAT1, as well as post-transcriptional mechanisms including microRNAs (e.g., miR-141, miR-223) and proteolytic shedding by ADAM proteases to produce sICAM-1, which acts as a decoy receptor or biomarker in circulation.^[3]^[4] ICAM-1 plays pivotal roles in pathology, contributing to chronic inflammation in conditions like atherosclerosis, rheumatoid arthritis, and asthma via excessive leukocyte recruitment; it promotes tumorigenesis and metastasis in cancers such as melanoma, breast, and lung carcinoma by enhancing tumor cell adhesion and survival signaling; and it is implicated in susceptibility to infections like malaria and in injury resolution processes, with elevated sICAM-1 levels serving as a prognostic indicator in sepsis, cardiovascular disease, and malignancy.^[3]^[4]^[2]

Introduction and Discovery

Definition and Basic Properties

ICAM-1 (Intercellular Adhesion Molecule 1), also known as CD54, is a transmembrane glycoprotein belonging to the immunoglobulin superfamily.^[2] It is encoded by the ICAM1 gene in humans, located on chromosome 19p13.2.^[2] This cell surface protein is typically expressed on endothelial cells and immune system cells, playing a foundational role in cellular adhesion processes.^[3] The core structure of ICAM-1 includes five extracellular immunoglobulin-like domains (D1–D5) exposed to the cell surface, a single transmembrane helix that anchors it in the membrane, and a short cytoplasmic tail of approximately 28 amino acids involved in intracellular interactions. Alternative splicing generates isoforms, including a soluble form (sICAM-1) lacking the transmembrane and cytoplasmic domains.^[2]^[3] Due to N- and O-linked glycosylation, the mature protein exhibits a molecular weight of approximately 60-114 kDa, with variations depending on the degree of glycosylation across its immunoglobulin-like domains.^[3] ICAM-1 functions primarily as a ligand for leukocyte β2-integrins, such as lymphocyte function-associated antigen 1 (LFA-1; αLβ2; CD11a/CD18) and Mac-1 (αMβ2; CD11b/CD18), thereby mediating essential cell-cell interactions during immune responses.^[5]^[3] Its expression is upregulated by inflammatory cytokines, enhancing its availability in response to immune stimuli.^[3]

Historical Discovery

ICAM-1 was first described in 1986 as a novel intercellular adhesion molecule expressed on the surface of endothelial cells and other cell types, playing a key role in mediating leukocyte adhesion during inflammatory responses. Researchers at the time identified it using monoclonal antibodies that inhibited phorbol ester-stimulated homotypic aggregation of leukocytes, distinguishing it from the integrin LFA-1 while noting its inducible expression by inflammatory stimuli such as interleukin-1 (IL-1) and interferon-gamma (IFN-γ). This initial characterization highlighted ICAM-1's presence on cytokine-activated endothelial cells, where it facilitates the recruitment of immune cells to sites of inflammation.^[6]^[7] Subsequent studies in 1987 confirmed ICAM-1 as a direct ligand for LFA-1, with purification and reconstitution experiments demonstrating specific binding that supported cell adhesion under physiological conditions. The molecular cloning and sequencing of ICAM-1 were achieved in 1988, revealing its primary structure as a glycoprotein belonging to the immunoglobulin superfamily, with five extracellular Ig-like domains, a transmembrane region, and a short cytoplasmic tail; this work also underscored its homology to neural cell adhesion molecule (NCAM) and its interaction with the integrin family. These findings established ICAM-1's structural basis for adhesive functions in immune interactions.^[8] In 1989, during the Fourth International Workshop on Leukocyte Differentiation Antigens in Vienna, ICAM-1 was officially designated as the cluster of differentiation antigen CD54, standardizing its nomenclature within the leukocyte surface antigen system. This assignment reflected its recognition as a critical marker on various hematopoietic and non-hematopoietic cells involved in immune responses. Early investigations in the late 1980s and 1990s further linked ICAM-1 to microbial interactions, with confirmatory evidence in 1989 showing it serves as the primary cellular receptor for the major group of human rhinoviruses, enabling viral attachment and entry into host cells such as epithelial cells in the respiratory tract. This discovery, based on binding assays with purified ICAM-1 and monoclonal antibody inhibition, expanded ICAM-1's role beyond immune adhesion to viral pathogenesis.^[9]

Gene and Expression

Genomic Organization

The ICAM1 gene, which encodes intercellular adhesion molecule 1, is located on the short arm of human chromosome 19 at position 19p13.2.^[2] It spans approximately 15.8 kilobases (kb) of genomic DNA and consists of seven exons separated by six introns.^[10] Exon 1 encodes the signal peptide, exons 2 through 6 correspond to the five immunoglobulin-like extracellular domains, and exon 7 encodes the transmembrane and cytoplasmic domains.^[4] The promoter region of ICAM1, situated upstream of exon 1, is a CpG island-rich area that includes multiple transcription factor binding sites critical for inducible expression. Notably, it contains consensus sequences for NF-κB and AP-1, which facilitate rapid transcriptional activation in response to inflammatory stimuli. These elements are conserved and play a key role in coordinating gene expression under cytokine influence.^[11] Alternative splicing of the ICAM1 pre-mRNA generates multiple isoforms, including a soluble form known as sICAM-1, which lacks the transmembrane domain encoded by exon 7 and is secreted into the extracellular space.^[1] This isoform arises from exon skipping or alternative polyadenylation, resulting in truncated proteins with varying numbers of extracellular domains (typically two to five).^[12] Such splicing events contribute to the diversity of ICAM-1 functions in circulation. Several single nucleotide polymorphisms (SNPs) within the ICAM1 gene influence its expression and protein function. The rs5498 polymorphism (also denoted as K469E), located in exon 6, results in a lysine-to-glutamic acid substitution in the fifth immunoglobulin-like domain and is associated with elevated soluble ICAM-1 levels and altered endothelial expression.^[13] This variant has been linked to increased transcriptional activity and higher serum concentrations of sICAM-1 in various populations.^[14]

Regulation and Tissue Distribution

ICAM-1 is constitutively expressed at low basal levels on endothelial cells, fibroblasts, and select leukocytes, including lymphocytes and monocytes, under normal physiological conditions, with highest expression observed in lung and bone marrow tissues.^[2]^[3] This baseline expression supports minimal cell adhesion in non-inflammatory states.^[2] Expression of ICAM-1 is markedly upregulated in response to pro-inflammatory stimuli, particularly cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interferon-gamma (IFN-γ), which activate the nuclear factor kappa B (NF-κB) transcription factor pathway and STAT1 to drive transcriptional induction.^[3] This inducible mechanism enhances ICAM-1 surface levels on endothelial and epithelial cells within hours of cytokine exposure.^[15] Post-transcriptional regulation also plays a role, including suppression by microRNAs such as miR-141 and miR-223, and generation of sICAM-1 through proteolytic shedding by ADAM proteases.^[3] Conversely, anti-inflammatory agents downregulate ICAM-1; glucocorticoids, such as dexamethasone, suppress its expression by inhibiting NF-κB activation and translocation in endothelial cells.^[16] Similarly, interleukin-10 (IL-10) reduces ICAM-1 levels on IL-1-activated endothelial cells, thereby limiting leukocyte adhesion.^[17] A soluble isoform of ICAM-1 (sICAM-1), generated through proteolytic shedding from the cell surface, circulates in plasma and acts as a biomarker for systemic inflammation, with elevated levels correlating to disease activity in conditions like rheumatoid arthritis and sepsis.^[18] Regarding tissue distribution, ICAM-1 exhibits elevated expression in inflamed sites, such as the synovium of rheumatoid arthritis joints where it is prominently displayed on endothelial and synovial lining cells.^[19] In contrast, healthy brain endothelium maintains low ICAM-1 levels, contributing to the blood-brain barrier's restrictive nature under basal conditions.^[20]

Molecular Structure

Domain Architecture

ICAM-1 is a type I transmembrane protein characterized by an extracellular region composed of five immunoglobulin-like (Ig-like) domains (D1–D5), a single hydrophobic transmembrane helix, and a short cytoplasmic tail of approximately 28 amino acids. The Ig-like domains belong to the immunoglobulin superfamily (IgSF), with D1 and D3 classified in the I-set, D2 and D4 in the C2-set (also known as I2-set), and D5 featuring a distorted C2-set topology.^[21]^[3] The extracellular domains form an elongated, rod-like structure that projects from the cell surface, enabling interactions with extracellular ligands, while the single-span transmembrane domain (spanning residues approximately 480–502) anchors the protein in the lipid bilayer.^[3]^[22] Each Ig-like domain adopts a beta-sandwich fold consisting of two antiparallel beta-sheets packed against each other, a hallmark of IgSF proteins that confers stability and flexibility to the overall architecture. The N-terminal D1 domain, located at the distal tip, is structurally primed for ligand engagement through exposed loops, though its primary role in binding is supported by the domain's conserved beta-sheet framework. Crystal structures determined in the late 1990s, such as the 2.2 Å resolution model of D1–D2 (PDB: 1IAM), reveal a compact, horseshoe-like arrangement of beta-strands in these domains, with D1 featuring an A/B/E/G-sheet and a C/C'/F-sheet connected by a disulfide bond.^[23] Similarly, the structure of D3–D5 (PDB: 1P53) highlights the continuity of this beta-rich motif across the extracellular region, underscoring the modular nature of ICAM-1's domain organization.^[24] The cytoplasmic tail lacks intrinsic enzymatic activity but contains motifs that facilitate intracellular signaling and cytoskeletal associations upon extracellular stimulation. Additionally, the protein exhibits potential for dimerization within the membrane, primarily mediated by domain D4, where edge beta-strands from opposing monomers fuse to form a super beta-sandwich, burying approximately 980 Å² of surface area per subunit and stabilized by 12 hydrogen bonds. This dimerization propensity, observed in crystal structures and supported by the transmembrane region's hydrophobic interactions, may enhance avidity in cellular contexts.^[21]

Post-Translational Modifications

ICAM-1 undergoes extensive N-linked glycosylation at eight asparagine residues primarily located within its extracellular immunoglobulin-like domains D2 through D4.^[25] These modifications add complex and high-mannose oligosaccharides, capped in many cases with sialic acid, which collectively account for approximately 30-50% of the protein's mature molecular weight, elevating it from a core polypeptide of about 60 kDa to 76-114 kDa.^[4] The glycosylation enhances protein stability, proper folding, and cell surface localization, while also modulating ligand binding affinity; for instance, high-mannose glycoforms promote stronger monocyte adhesion compared to fully processed complex forms.^[3] In addition to N-linked modifications, ICAM-1 features limited O-linked glycosylation at two serine or threonine residues, primarily in the extracellular region, though these contribute less to overall mass and function than N-glycans.^[22] Phosphorylation occurs predominantly in the short cytoplasmic tail, with key sites including tyrosine 485, which is targeted by Src and c-Met kinases upon ligand-induced clustering.^[25] This phosphorylation regulates intracellular signaling, cytoskeletal rearrangements, and protein trafficking, thereby influencing ICAM-1's role in cell adhesion dynamics without altering its core structure.^[26] Proteolytic cleavage of the membrane-bound form generates a soluble variant (sICAM-1) through ectodomain shedding mediated by ADAM10, ADAM17, and matrix metalloproteinase-9 (MMP-9) at sites proximal to the transmembrane domain.^[27] This process, often triggered by inflammatory stimuli, releases a circulating form that retains partial ligand-binding capacity and can modulate systemic immune responses by competing with membrane ICAM-1.^[28] Phosphorylation at Tyr485 facilitates cleavage by MT1-MMP, linking these modifications to enhanced leukocyte transmigration.^[25] The profile of these modifications varies by cell type, with endothelial cells typically exhibiting higher sialylation and complex N-glycan capping on ICAM-1, which fine-tunes adhesion and reduces non-specific interactions, compared to immune cells where high-mannose forms predominate under inflammatory conditions to boost rapid leukocyte recruitment.^[3] Such differences arise from cell-specific glycosyltransferase expression and contribute to tissue-specific regulation of ICAM-1 activity.^[29]

Biological Functions

Cell Adhesion and Migration

ICAM-1 serves as a key adhesion molecule on endothelial cells, mediating the firm attachment of leukocytes to the vascular wall primarily through interactions with β2-integrins, such as LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18). These integrin bindings enable leukocytes to transition from loose rolling to stable arrest under physiological shear stress conditions in the bloodstream, facilitating their recruitment to sites of inflammation.^[30]^[31]^[32] This adhesion is integral to the multi-step process of leukocyte extravasation, where ICAM-1 contributes to the stabilization of rolling initiated by selectins, promotes firm adhesion, and supports subsequent diapedesis through the endothelial barrier. During inflammation, upregulated ICAM-1 expression on endothelium enhances these interactions, allowing leukocytes to crawl and transmigrate efficiently into tissues. Studies using knockout models and blocking antibodies have shown that disruption of ICAM-1/β2-integrin binding severely impairs this extravasation, underscoring its essential role.^[30]^[33]^[34] Beyond leukocytes, ICAM-1 binds soluble ligands like fibrinogen, which bridges ICAM-1 on endothelium to activated platelets or leukocytes, promoting platelet-leukocyte aggregates and aiding in hemostasis and early wound repair. ICAM-1 also interacts with hyaluronan, a glycosaminoglycan in the extracellular matrix, which supports leukocyte motility and matrix remodeling during tissue healing processes. These additional bindings expand ICAM-1's role in coordinating cellular responses at injury sites.^[35]90367-Y)^[36]^[37] In vitro assays, such as the modified Stamper-Woodruff binding assay on frozen endothelial sections, have demonstrated the shear-resistant nature of ICAM-1-mediated leukocyte adhesion, where rotating samples simulate blood flow and reveal robust, integrin-dependent attachments that withstand detachment forces. Parallel flow chamber experiments further confirm that ICAM-1/LFA-1 interactions maintain adhesion under dynamic shear stresses up to 2 dyn/cm², mimicking venular conditions. These assays highlight the mechanical strength of ICAM-1 in supporting migration without relying on static binding.^[38]^[39]^[40]

Immune Signaling and Other Roles

Upon ligation by integrins such as LFA-1, the cytoplasmic tail of ICAM-1 recruits Src family kinases, including Lyn, leading to rapid tyrosine phosphorylation and activation of downstream signaling cascades.^[41] This activation initiates the MAPK/ERK pathway and PI3K/Akt signaling, which promote cytoskeletal rearrangements essential for cellular responses like endothelial permeability changes during inflammation.^[42] In endothelial cells, ICAM-1 engagement further involves SHP-2-mediated Src activation, enhancing PI3K signaling and eNOS phosphorylation to facilitate leukocyte transmigration without direct mention of adhesion mechanics.^[43] ICAM-1 also serves a costimulatory function in adaptive immunity, particularly in T-cell activation and antigen presentation by antigen-presenting cells (APCs). On APCs, ICAM-1 expression lowers the antigen threshold required for naïve T-cell activation, amplifying signaling through LFA-1 engagement to enhance proliferation and cytokine production.^[44] In T cells themselves, ICAM-1 acts as an alternative costimulatory receptor, synergizing with CD28/B7 pathways via PI3K to promote survival and effector differentiation, distinct from primary adhesion roles.^[45] This costimulation is particularly evident in low-antigen scenarios, where ICAM-1/B7 co-expression on APCs markedly boosts IL-2 secretion and T-cell expansion.^[46] Beyond immune signaling, ICAM-1 functions as a cellular receptor for certain viruses, facilitating entry into host cells. It serves as the primary receptor for the major group of human rhinoviruses, binding via the N-terminal domain to enable viral attachment and uncoating in respiratory epithelial cells.90688-0) Similarly, ICAM-1 mediates entry of Coxsackievirus A21, with the binding site overlapping rhinovirus recognition regions in the viral canyon, highlighting its role in non-enveloped virus infections.^[47] In reproductive biology, ICAM-1 regulates tight junction dynamics in the blood-testis barrier during spermatogenesis; its expression in Sertoli cells co-localizes with junctional proteins like ZO-1, supporting germ cell transit while maintaining barrier integrity.^[48] The soluble form of ICAM-1 (sICAM-1), generated by proteolytic shedding or alternative splicing, modulates immune responses by acting as a decoy receptor that competes with membrane-bound ICAM-1 for integrin binding, such as LFA-1 on leukocytes.^[3] This competition reduces leukocyte adhesion and transmigration at inflammatory sites, exerting anti-inflammatory effects at elevated levels, as observed in conditions with high sICAM-1 circulation. In T-cell contexts, sICAM-1 inhibits costimulatory signaling by blocking LFA-1 interactions, thereby dampening excessive activation and cytokine release.

Protein Interactions

Key Binding Partners

ICAM-1 primarily interacts with β2-integrins on leukocytes, serving as a key ligand for facilitating cell adhesion. The most prominent binding partner is lymphocyte function-associated antigen-1 (LFA-1, CD11a/CD18), which binds to the N-terminal domains (D1 and D2) of ICAM-1 with an affinity in the range of 10-100 nM under physiological conditions.^[49] Macrophage-1 antigen (Mac-1, CD11b/CD18) also binds ICAM-1, primarily through its interaction with the third immunoglobulin-like domain (D3), enabling adhesion of monocytes and neutrophils.^[50] Additionally, complement receptor 4 (CD11c/CD18) engages ICAM-1 via a site in the fourth domain (D4), supporting interactions with dendritic cells and other antigen-presenting cells.^[51] ICAM-1 functions as a receptor for certain viruses, particularly those in the Picornaviridae family. Major group rhinoviruses bind to the D1 domain of ICAM-1, utilizing this interaction for cellular entry during respiratory infections.^[52] Similarly, Coxsackievirus A21 attaches to a conserved site within the D1 domain, overlapping with the rhinovirus binding region and facilitating viral uncoating.^[47] ICAM-1 also serves as a receptor for Plasmodium falciparum-infected erythrocytes via the parasite's erythrocyte membrane protein 1 (PfEMP1), binding primarily to the D1 domain of ICAM-1 in a site that overlaps but is distinct from the LFA-1 binding region; this interaction promotes cytoadherence in malaria pathology.^[53] Other notable partners include fibrinogen, which binds to the first immunoglobulin domain of ICAM-1, potentially bridging leukocytes to endothelial surfaces.^[54] ICAM-1 also associates with ezrin, a cytoskeletal linker protein that connects the adhesion molecule to the actin cytoskeleton, aiding in membrane organization.^[55] Furthermore, ICAM-1 can bind hyaluronic acid, an extracellular matrix component, through sites that may influence cell-matrix interactions.^[56] Soluble forms of ICAM-1, generated by proteolytic shedding, retain the ability to interact with the same β2-integrins (LFA-1, Mac-1, and CD11c/CD18) in circulation, modulating systemic immune responses.^[57]

Interaction Pathways

The interaction between ICAM-1 and integrins, such as LFA-1 (αLβ2), initiates inside-out signaling pathways that enhance leukocyte adhesion. Upon chemokine stimulation, Rap1 GTPase is activated, recruiting talin and kindlin to the integrin cytoplasmic tails, which stabilizes the integrin in a high-affinity conformation for ICAM-1 binding, thereby promoting firm adhesion. This Rap1-mediated mechanism is essential for modulating integrin avidity without relying on other pathways like PI3K or PKC.^[58]^[59]^[60] ICAM-1 participates in inflammatory cascades through a feedback loop involving NF-κB transcription factor and pro-inflammatory cytokines. Cytokines like TNF-α and IL-1β induce NF-κB activation, which transcriptionally upregulates ICAM-1 expression on endothelial cells, facilitating leukocyte recruitment. In turn, ICAM-1 engagement amplifies cytokine production and sustains NF-κB signaling, perpetuating the inflammatory response.^[3]^[61]^[62] ICAM-1 integrates into the multi-step adhesion model via crosstalk with selectins and chemokine signaling. Initial leukocyte rolling mediated by selectins (e.g., P-selectin or E-selectin) exposes cells to endothelial chemokines, which trigger G-protein-coupled receptor signaling to activate Rap1 and subsequent integrin-ICAM-1 binding for firm arrest. This sequential interplay ensures efficient leukocyte extravasation at inflammatory sites.^[63]^[64] In viral infection pathways, ICAM-1 serves as a receptor for major-group human rhinoviruses (HRV), where the ICAM-1-HRV complex undergoes clathrin-mediated endocytosis for viral entry. Binding induces receptor clustering and recruitment of clathrin adaptors, leading to internalization into early endosomes where low pH triggers viral uncoating and genome release.^[65]^[66]^[67]

Clinical and Pathological Significance

Role in Inflammatory and Autoimmune Diseases

ICAM-1 plays a central role in the pathogenesis of inflammatory and autoimmune diseases by facilitating leukocyte adhesion and transmigration across endothelial barriers, thereby promoting tissue infiltration and chronic inflammation. In these conditions, upregulated ICAM-1 expression on endothelial cells and leukocytes enhances the recruitment of inflammatory cells, such as monocytes and eosinophils, exacerbating disease progression. Soluble forms of ICAM-1 (sICAM-1), shed from cell surfaces, often circulate at elevated levels and serve as biomarkers correlating with disease severity. In atherosclerosis, ICAM-1 is elevated on endothelial cells in vessel walls, where it promotes monocyte recruitment and adhesion, contributing to plaque formation and vascular inflammation. Studies in animal models demonstrate that aldosterone-induced atherosclerosis relies on ICAM-1-mediated mechanisms, as ICAM-1 knockout mice exhibit reduced plaque size, lipid accumulation, and inflammatory cell infiltration compared to wild-type counterparts. This adhesion molecule's expression is particularly prominent in early lesion-prone sites, independent of cholesterol levels, underscoring its role in initiating monocyte extravasation. Rheumatoid arthritis (RA) involves ICAM-1 upregulation in synovial tissues, facilitating leukocyte infiltration into joints and perpetuating synovitis. Circulating sICAM-1 levels are significantly higher in RA patients' sera compared to healthy controls or osteoarthritis patients, with modest correlations to disease activity markers like joint scores and erythrocyte sedimentation rate. In multiple sclerosis (MS), ICAM-1 supports the transmigration of autoreactive T cells across the blood-brain barrier, enabling central nervous system (CNS) inflammation. During MS relapses, sICAM-1 concentrations increase in cerebrospinal fluid, while cell-surface ICAM-1 on CD3+ T cells decreases, indicating active shedding and serving as a marker of disease activity. ICAM-1 also contributes to asthma and allergic responses by enhancing eosinophil adhesion to airway epithelium. In inflamed bronchial endothelium, ICAM-1 expression is upregulated, partially mediating eosinophil-endothelial interactions that drive airway eosinophilia and hyperresponsiveness, as evidenced in primate models where ICAM-1 blockade reduced these features. Post-2020 research highlights ICAM-1's involvement in COVID-19-related pathology, where elevated endothelial ICAM-1 expression in lung tissues correlates with severe inflammation, leukocyte recruitment, and cytokine storms involving IL-6 and TNF-α, exacerbating endothelial dysfunction and thrombosis.

Therapeutic Targeting and Applications

Therapeutic strategies targeting ICAM-1 primarily aim to inhibit its expression or function to reduce leukocyte adhesion and inflammation in various diseases. Monoclonal antibodies against ICAM-1, such as enlimomab, a murine anti-human ICAM-1 antibody, were investigated in the 1990s and early 2000s for preventing ischemia-reperfusion injury in conditions like acute ischemic stroke and renal transplantation. In the Enlimomab Acute Stroke Trial (EAST), involving 625 patients, enlimomab failed to improve neurological outcomes and was associated with worsened disability, likely due to immunogenicity and proinflammatory effects from the murine origin, leading to its withdrawal from further development. Similarly, in renal transplant trials, enlimomab did not reduce the rate of acute rejection or delayed graft function and showed no significant difference in adverse events, including post-transplant infections, compared to placebo, contributing to its discontinuation.^[68]^[69]^[70] Small molecules and antisense oligonucleotides represent alternative approaches to modulate ICAM-1. Natriuretic peptides, including atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP), have been shown to suppress TNF-α-induced ICAM-1 expression on endothelial cells, thereby inhibiting leukocyte recruitment and vascular inflammation in preclinical models of ischemia-reperfusion and sepsis. Cannabinoid receptor 2 (CB2) agonists, such as JWH-133 and HU-308, reduce ICAM-1 and VCAM-1 expression in activated endothelial cells by blocking NF-κB signaling, demonstrating anti-atherosclerotic effects in animal models through decreased monocyte adhesion. Alicaforsen, an antisense oligonucleotide targeting ICAM-1 mRNA, has undergone phase II and III trials for inflammatory bowel disease (IBD), including Crohn's disease and chronic pouchitis; while phase II rectal administration showed remission in some steroid-dependent patients with pouchitis and was well-tolerated, the phase III trial for chronic refractory pouchitis did not meet its primary endpoints, though it demonstrated safety and some clinical signals; intravenous dosing in Crohn's disease showed limited efficacy in broader cohorts.^[71]^[72]^[73]^[74]^[75]^[76]^[77] Emerging therapies leverage gene editing and targeted delivery systems to downregulate or exploit ICAM-1. CRISPR-based gene knockout of ICAM-1 in hypoimmune cells has been explored to reduce immune cell adhesion in autoimmunity models, enhancing graft survival by limiting T-cell and innate immune responses without broad immunosuppression. ICAM-1-targeted nanoparticles, such as those conjugated with anti-ICAM-1 antibodies or peptides and loaded with drugs like paclitaxel, facilitate site-specific delivery to inflamed endothelium or tumor cells overexpressing ICAM-1, improving anti-cancer efficacy in breast cancer metastasis models and reducing monocyte adhesion in inflammatory sites. These approaches address challenges like off-target effects by focusing on upregulated ICAM-1 in pathology.^[78]^[79]^[80]^[81] Post-2020 research has highlighted ICAM-1's potential in antiviral therapies, particularly by blocking viral entry. Anti-ICAM-1 antibodies inhibit rhinovirus binding and replication in airway epithelial models, as ICAM-1 serves as the primary receptor for major-group rhinoviruses responsible for ~60% of common colds; domain-specific antibodies reduced viral load in vivo, suggesting applications for acute respiratory infections. In COVID-19, elevated soluble ICAM-1 correlates with endothelial dysfunction and disease severity, prompting investigations into ICAM-1 modulation as an adjunct to mitigate coagulopathy and inflammation, though clinical trials remain preclinical or exploratory as of 2025. As of 2025, no ICAM-1-targeted therapies have received regulatory approval for clinical use, though research into ICAM-1 modulation for long COVID and other inflammatory conditions continues in preclinical stages.^[82]^[83]^[84]^[85]^[86]^[87]

References

[1]
ICAM1 intercellular adhesion molecule 1 [Homo sapiens (human)] - Gene - NCBI
**ICAM-1 Summary**
[2]
ICAM-1: A master regulator of cellular responses in inflammation ...
ICAM-1 is a cell surface glycoprotein and an adhesion receptor that is best known for regulating leukocyte recruitment from circulation to sites of ...
[3]
Intercellular Adhesion Molecule 1: More than a Leukocyte ... - MDPI
In this review article, the ICAM1 gene and ICAM-1 protein are introduced, and their regulation is summarized. The roles of ICAM-1 in the immune system and a ...
[4]
Intercellular Adhesion Molecule 1 (ICAM-1): Getting a Grip on ... - NIH
The discovery of ICAM-1 (CD54) as a ligand of the β2 integrin lymphocyte function-associated antigen (LFA)-1 (αLβ2 or CD11a-CD18) established the receptor ...
[5]
A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1
It is proposed that ICAM-1 may be a ligand in many, but not all, LFA-1-dependent adhesion reactions. Publication types. Research Support, Non- ...Missing: discovery | Show results with:discovery
[6]
Induction by IL 1 and interferon-gamma: tissue distribution ... - PubMed
ICAM-1 is a cell surface glycoprotein originally defined by a monoclonal antibody (MAb) that inhibits phorbol ester-stimulated leukocyte aggregation.
[7]
ICAM, an adhesion ligand of LFA-1, is homologous to the neural cell ...
Feb 18, 1988 · LFA-1 mediates the leukocyte adhesion reactions underlying cytolytic conjugate formation, helper T-cell interactions, and antibody-dependent ...<|control11|><|separator|>
[8]
A cell adhesion molecule, ICAM-1, is the major surface receptor for ...
We demonstrate identity between the receptor for the major group of rhinoviruses and ICAM-1. A major group rhinovirus binds specifically to purified ICAM-1.Missing: et al
[9]
Association of intercellular adhesion molecule 1 (ICAM1) with ... - NIH
Jan 22, 2013 · In this review, we present genomic structure, variation, and ... Genetic influences of the intercellular adhesion molecule 1 (ICAM-1) ...Linkage Of The Icam1 Gene To... · Icam1 As A Biomarkers For... · Icam1 As A Target For Drug...
[10]
Transcriptional Regulation of the Intercellular Adhesion Molecule-1 ...
Six potential NF-κB sites have been identified in the ICAM-1 5′-flanking sequence and first intron, but which, if any, are involved in cytokine activation of ...Materials And Methods · Luciferase And... · Electrophoretic Mobility...Missing: AP- | Show results with:AP-
[11]
147840 - INTERCELLULAR ADHESION MOLECULE 1; ICAM1 - OMIM
▼ Description ICAM1 is an inducible glycoprotein of the immunoglobulin (Ig) superfamily that contains 5 distinct Ig-like domains, a transmembrane domain, and a ...Missing: 1980s | Show results with:1980s
[12]
ICAM-1 isoforms: specific activity and sensitivity to cleavage by ...
The ICAM-1 gene, however, gives rise to the expression of five alternative splice variants containing two, three, or four Ig-like domains. In this work, we have ...
[13]
Polymorphism rs5498 of the ICAM-1 gene affects the progression of ...
The rs5498 (K469E) polymorphism of the ICAM-1 gene leads to an increase in the level of serum ICAM. We investigated the association between the rs5498 ...
[14]
Intracellular Adhesion Molecule-1 K469E Gene Polymorphism and ...
A recent genome wide association study has demonstrated a strong correlation between K469E polymorphism and sICAM-1 levels [20]. Thus, the K469E polymorphism of ...
[15]
NF-κB regulates thrombin-induced ICAM-1 gene expression in ...
The intron-1 contains 2 putative NF-κB binding sites. PCR primers were designed to amplify fragments A, B, C, and D that bear consensus NF-κB binding sequences ...
[16]
https://doi.org/10.1074/jbc.271.32.19612
[17]
IL-10 Inhibits the Adhesion of Leukocytic Cells to IL-1 ... - PubMed
IL-10 also down-regulated the expression of ICAM-1 and VCAM-1 on IL-1-activated endothelial cells. IL-10-treated THP-1 cells adhered less than untreated THP-1 ...
[18]
The association between soluble intercellular adhesion molecule-1 ...
Soluble ICAM-1 (sICAM-1) is a circulating form of ICAM-1. sICAM-1 is increased in inflammation and found in various body fluids, such as serum, sputum, synovial ...
[19]
Expression of Adhesion Molecules in Synovia of Patients with ...
In rheumatoid arthritis, adhesion molecules, including P-selectin, LFA-1, ICAM-1, VLA-4, and VCAM-1, are up-regulated within the intense proinflammatory milieu ...
[20]
Alterations in blood-brain barrier ICAM-1 expression and brain ...
ICAM-1 expression in cerebral microvessels, under basal conditions, is low (45); however, ICAM-1 is markedly increased on the luminal surface of endothelial ...
[21]
Structural plasticity in Ig superfamily domain 4 of ICAM-1 ... - PNAS
ICAM-1 consists of five extracellular IgSF domains (D1–D5), a hydrophobic transmembrane domain, and a short cytoplasmic domain (1). In its native state on the ...Missing: architecture | Show results with:architecture
[22]
https://www.uniprot.org/uniprotkb/P05362/entry
[23]
1P53: The Crystal Structure of ICAM-1 D3-D5 fragment - RCSB PDB
May 4, 2004 · We have determined the 3.0 A crystal structure of the three C-terminal domains 3-5 (D3-D5) of ICAM-1. Combined with the previously known N-terminal two-domain ...Missing: Casanova 1991
[24]
ICAMs in Immunity, Intercellular Adhesion and Communication - MDPI
Upon receptor aggregation, ICAM-1 can be phosphorylated on Tyr485 by Src and Met tyrosine-protein kinases [67,68]. This posttranslational modification allows ...Icams In Immunity... · 2. Icams In The Immune... · 2.1. Icam-1 (cd54)<|control11|><|separator|>
[25]
p05362 · icam1_human - UniProt
ICAM proteins are ligands for the leukocyte adhesion protein LFA-1 (integrin alpha-L/beta-2). · (Microbial infection) Acts as a receptor for major receptor group ...Missing: scientific review
[26]
Src Phosphorylation of Endothelial Cell Surface Intercellular ...
The data presented show that ICAM-1 Tyr518 phosphorylation leads to ICAM-1 clustering, increased binding of YN1/1.7.4 mAb, and a 3-fold increase in PMN adhesion ...
[27]
ADAM10-Mediated Cleavage of ICAM-1 Is Involved in Neutrophil ...
Jan 25, 2021 · We conclude that endothelial ADAM10 contributes in part to neutrophil transendothelial migration by cleaving ICAM-1, thereby supporting the release of ...
[28]
Tumor Necrosis Factor-α-converting Enzyme (TACE/ADAM-17 ...
This profile suggests the involvement of the ADAM family of proteases in the cleavage of ICAM-1. ... ICAM-1 is shed as soluble ICAM-1 (sICAM-1) in blood ...
[29]
manifold roles of sialic acid for the biological functions of endothelial ...
Feb 10, 2020 · The major role of membrane-bound ICAM-1 is to mediate the second step in the extravasation of immune cells into inflamed tissue occurring after ...
[30]
Hug Tightly and Say Goodbye: Role of Endothelial ICAM-1 in ...
ICAM-1 is a cell surface glycoprotein of 505 amino acids with a molecular weight ranging from 76 to 114 kDa, depending upon extent of tissue-specific ...Dual Role Of Icam-1 In... · Icam-1 As A Signaling... · Pkc Signaling Of Icam-1
[31]
I-Domain of Lymphocyte Function-Associated Antigen-1 Mediates ...
In their active state, β2-integrins, such as LFA-1, mediate the firm arrest of leukocytes by binding intercellular adhesion molecules (ICAMs) expressed on ...
[32]
A role for ICAM-1 in maintenance of leukocyte-endothelial cell ...
It binds to the family of β2-integrins, leukocyte function antigen-1 (LFA-1, CD11a/CD18), and Mac-1 (CD11b/CD18), thereby mediating cell-cell adhesive ...
[33]
Review leukocyte migration into inflamed tissues - ScienceDirect.com
Nov 20, 2014 · The primary step in leukocyte migration is the establishment of weak and transient adhesive interactions between leukocytes and endothelial ...
[34]
Coordinated Redistribution of Leukocyte LFA-1 and Endothelial Cell ...
Dec 20, 2004 · We demonstrate in the previous paragraphs that neutrophil LFA-1 redistributes around the site of neutrophil penetration, along with both ICAM-1 ...Missing: sources | Show results with:sources
[35]
Interactions of intercellular adhesion molecule-1 with fibrinogen
The binding of plasma protein fibrinogen (Fg) to intercellular adhesion molecule-1 (ICAM-1) on endothelial cells mediates the attachment of leukocytes and ...Missing: hyaluronan healing primary sources
[36]
Identification of IHABP, a 95 kDa intracellular hyaluronate binding ...
Recognition of and binding to hyaluronan is mediated by cell surface receptors. Three of them, CD44, ICAM-1 and RHAMM (receptor for hyaluronic acid mediated ...<|control11|><|separator|>
[37]
Recent applications and molecular mechanisms of hyaluronic acid ...
This review summarizes the recent advances and applications of the molecular mechanisms of HA and its derivatives in the field of anti-aging and wound healing.
[38]
T Lymphocyte Adhesion Mechanisms within Inflamed Human Kidney
We have developed a modified Stamper-Woodruff assay system to analyze mechanisms of functional T cell adhesion to cryostat sections of renal biopsy material ...
[39]
LFA-1 is required for retention of effector CD8 T cells in mouse lungs
In vitro binding assay. Using the Stamper-Woodruff assay, we next analyzed the role of LFA-1/ICAM-1 and VLA-4/VCAM-1 in D4 binding to frozen lung sections.
[40]
Arteriogenesis Proceeds via ICAM-1/Mac-1- Mediated Mechanisms
ICAM-1/Mac-1-mediated monocyte adhesion to the endothelium of collateral arteries is an essential step for arteriogenesis, whereas this process can proceed via ...Missing: primary | Show results with:primary
[41]
Signaling through intercellular adhesion molecule 1 (ICAM-1) in a B ...
Apr 4, 1997 · In vitro kinase assays showed that Lyn kinase was activated within 1 min after ICAM-1 cross-linking. In addition, ICAM-1 cross-linking resulted ...Missing: cytoplasmic | Show results with:cytoplasmic
[42]
ICAM-1–activated Src and eNOS signaling increase endothelial cell ...
These results collectively show that ICAM-1–activated Src and eNOS signaling sequentially induce PECAM-1–mediated PMN transendothelial migration.Missing: cytoplasmic Lyn
[43]
ICAM-1–activated Src and eNOS signaling increase endothelial cell ...
Multiple signaling pathways, such as Ca2+, RhoA, RhoG, MAPK (p38), and Src, have been invoked to explain the mechanism of ICAM-1 activation and clustering.Missing: cytoplasmic Lyn
[44]
ICAM-1–dependent tuning of memory CD8 T-cell responses ... - PNAS
Expression of ICAM-1 by the APCs also lowers the concentration of antigen required to activate a naïve T cell (5), thereby enhancing the strength of antigenic ...
[45]
The outcome of T-cell costimulation through intercellular adhesion ...
Costimulation through ICAM-1 provided greater protection from apoptosis than costimulation through LFA-1, especially in cells having divided more than three ...
[46]
Costimulatory requirements of naive CD4 + T cells. ICAM-1 or B7-1 ...
Jul 1, 1995 · However, APC expressing both ICAM-1 and B7-1 were much better stimulators of proliferation and IL-2 secretion at low cell numbers, and were far ...<|separator|>
[47]
Interaction of Coxsackievirus A21 with Its Cellular Receptor, ICAM-1
The site of ICAM-1 binding within the canyon of CAV21 overlaps the site of receptor recognition utilized by rhinoviruses and polioviruses. Interactions within ...
[48]
Intercellular adhesion molecule-1 is a regulator of blood–testis ...
Dec 1, 2012 · Initial experiments showed ICAM-1 to co-immunoprecipitate and co-localize with tight junction and basal ectoplasmic specialization proteins such ...
[49]
Rational Design of Intercellular Adhesion Molecule-1 (ICAM-1 ...
The affinity of the HA αL I domain for wild-type ICAM-1 is low (KD = 185 ± 12 nM) (9) compared with many other protein-protein interactions. Enhancement of this ...
[50]
Binding of the integrin Mac-1 (CD11b/CD18) to the third ... - Cell Press
Both the integrins LFA-1 and Mac-1 bind to ICAM-1, an immunoglobulin superfamily member. Previously, we localized the binding sites of LFA-1 and the major ...Missing: key CD11c/
[51]
Interaction of ICAM‐1 with β2‐integrin CD11c/CD18 ...
Dec 6, 2005 · The integrin CD11c/CD18 plays a role in leukocyte and cell matrix adhesion and is highly expressed in certain hematopoietic malignancies.
[52]
The structure of the two amino-terminal domains of human ICAM-1 ...
The normal function of human intercellular adhesion molecule-1 (ICAM-1) is to provide adhesion between endothelial cells and leukocytes after injury or ...Missing: review | Show results with:review
[53]
Molecular identification of a novel fibrinogen binding site on the first ...
Jan 3, 1997 · Binding of fibrinogen to intercellular adhesion molecule 1 (ICAM-1) enhances leukocyte adhesion to endothelium by acting as a bridging molecule between the two ...Missing: D4 hyaluronic acid
[54]
Association of ezrin with intercellular adhesion molecule-1 and
Aug 21, 1998 · The results indicate an interaction of ezrin with ICAM-1 and ICAM-2 and suggest a regulatory role of phosphoinositide signaling pathways in regulation of ICAM- ...
[55]
Accessible hyaluronan receptors identical to ICAM-1 in mouse mast ...
Mar 3, 1995 · ICAM-1 staining was dramatically increased after hyaluronidase treatment of the sections, indicating that the HA is bound to these receptors and ...
[56]
A Functional Analysis on the Interspecies Interaction ... - Frontiers
Dec 20, 2017 · We have performed functional studies analyzing the ability of human soluble ICAM-1 and human/mouse LFA-1 derived peptides to inhibit cell aggregation and ...Icam-1 Chimeras And... · Analysis Of Icam-1 And Lfa-1... · Cell Adhesion Assays
[57]
Rap1 translates chemokine signals to integrin activation, cell ...
Apr 21, 2003 · The small GTPase Rap1 is a potent inside-out signal that functions in a distinct manner from PI3K and PKC, and increases the adhesive ...
[58]
Essential role for Rap1 GTPase and its guanine exchange factor ...
Rap1 was required for LFA-1 affinity modulation leading to cell adhesion to ICAM-1 but not for Mn2+-induced outside-in LFA-1 activation, demonstrating a ...
[59]
The Critical Cytoplasmic Regions of the αL/β2 Integrin in Rap1 ...
Rap1 is a potent inside-out signal that increases LFA-1 adhesive activity. In this study, we have defined the cytoplasmic region of the αL and β2 integrin ...
[60]
ICAM‐1 expression is highly NF‐κB‐dependent in A549 cells - 2004
Jan 28, 2004 · This epithelium is biosynthetically active and acts as a source of multiple inflammatory cytokines, chemokines, prostanoids and other mediators ...Abstract · The establishment of ICAM-1... · Effect of SB203580...
[61]
Up-regulation of intestinal nuclear factor kappa B and intercellular ...
Inflammatory response mediated by increased NF-κB activation and ICAM-1 expression may play an important role in the pathogenesis of acute gut mucosal injury ...
[62]
Concise Review: MSC Adhesion Cascade—Insights into Homing ...
Multistep model of leukocyte and mesenchymal stem cell (MSC) extravasation. Pro-inflammatory mediators initiate a cascade of endothelial and leukocyte/MSC ...Msc Extravasation · Selectin-Mediated Rolling · Integrin-Mediated Rolling
[63]
Chemokines, selectins and intracellular calcium flux - Frontiers
Neutrophil tethering on E-selectin activates beta-2 integrin binding to ICAM-1 through a mitogen-activated protein kinase signal transduction pathway. J ...
[64]
Internalization of human rhinovirus 14 into HeLa and ICAM-1 ...
Transmission electron microscopy of HeLa cells revealed that HRV14 was internalized via clathrin-coated pits and -coated vesicles. A minority of virus particles ...<|control11|><|separator|>
[65]
The clathrin endocytic pathway in viral infection | The EMBO Journal
Secondly, infection by human rhinoviruses appears to perturb clathrin‐mediated endocytosis ... ICAM‐1, the receptor for the major group of human rhinovirus that ...
[66]
Human Rhinovirus Type 2 Is Internalized by Clathrin-Mediated ...
Using several approaches, we investigated the importance of clathrin-mediated endocytosis in the uptake of human rhinovirus serotype 2 (HRV2).
[67]
Use of anti-ICAM-1 therapy in ischemic stroke - PubMed - NIH
Oct 23, 2001 · The authors conclude that anti-ICAM therapy with enlimomab is not an effective treatment for ischemic stroke in the model studied and, indeed, may ...
[68]
Use of anti-ICAM-1 therapy in ischemic stroke - Neurology.org
The purpose of the current clinical trial was to evaluate the use of enlimomab after ischemic stroke. Methods: A total of 625 patients with ischemic stroke ...
[69]
a report of the European Anti-ICAM-1 Renal Transplant Study Group
A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function ...Missing: injury | Show results with:injury
[70]
Natriuretic Peptides: It Is Time for Guided Therapeutic Strategies ...
Mar 7, 2023 · NPs reduce vascular inflammation by inhibiting the TNFα-induced expression of adhesion molecules, such as E-selectin and ICAM-1. NPs also ...
[71]
C-type natriuretic peptide inhibits leukocyte recruitment and ... - PNAS
We investigated whether CNP inhibits leukocyte recruitment and platelet aggregation and thereby exerts a potential antiinflammatory influence on the blood ...
[72]
Cannabinoid Receptor 2 Agonism Demonstrates Therapeutic ...
Jun 12, 2025 · For example, in coronary artery EC, CB2-selective agonists HU-308 and JWH-133 inhibited TNFα-induced ICAM-1 and VCAM-1 protein expression, NF-κB ...
[73]
Activation of cannabinoid CB2 receptor ameliorates atherosclerosis ...
The reduction in macrophage adhesion also correlated with significant reductions in the expression of VCAM-1, ICAM-1, and P-selectin, indicating that reduced ...
[74]
Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for ... - NIH
So far, published data about its potential role in IBD is inconsistent: Randomized, controlled trials fail to show efficacy of intravenous drug administration ...
[75]
Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease
People with Crohn's disease have been shown to over-produce ICAM-1 in their gut tissues. Alicaforsen works by blocking ICAM-1 messenger RNA, the "instruction" ...
[76]
Diminished immune cell adhesion in hypoimmune ICAM-1 knockout ...
Aug 12, 2025 · We identify the adhesion molecule ICAM-1 as a hypoimmune target that plays multiple critical roles in both adaptive and innate immune responses ...
[77]
Diminished Immune Cell Adhesion in Hypoimmune ICAM-1 ...
Jun 9, 2024 · We identified the adhesion molecule ICAM-1 as a novel hypoimmune target that plays multiple critical roles in both adaptive and innate immune ...
[78]
ICAM-1 Targeted Drug Combination Nanoparticles Enhanced ... - NIH
These data indicated that LFA1 on GT DcNPs may provide ICAM-1-targeted G and T drug combination delivery to advancing MBC cells found in lung tissues.
[79]
Tumor suppression via paclitaxel-loaded drug carriers that target ...
Targeting of ICAM-1 using Id-UAN nanoparticles, loaded with paclitaxel, resulted in increased anti-tumor activity compared to non-targeted carriers [106].
[80]
Targeting intercellular adhesion molecule-1 (ICAM-1) to reduce ...
Mar 22, 2022 · ICAM-1, which acts as a primary adhesion site for the HRV, could be effectively blocked to prevent viral-binding to host cells, thus preventing ...
[81]
An Anti-Human ICAM-1 Antibody Inhibits Rhinovirus-Induced ...
In this study, we demonstrate that an anti-ICAM-1 domain-specific antibody can effectively block entry and replication in an in vivo model of human rhinovirus ...
[82]
The main rhinovirus respiratory tract adhesion site (ICAM-1) is ...
Jan 5, 2017 · ICAM-1 is a major receptor for ~60% of human rhinoviruses, and non-typeable Haemophilus influenzae, two major pathogens in COPD.
[83]
Elevated Expression of Serum Endothelial Cell Adhesion Molecules ...
First, the endothelial cell adhesion markers FKN, VCAM-1, and ICAM-1 were elevated in COVID-19 patients. Second, the severity of COVID-19 was associated ...Missing: adjunct 2020-2025
[84]
Immunity, endothelial injury and complement-induced coagulopathy ...
Oct 19, 2020 · Most repurposed anti-viral drugs have failed to improve clinical outcomes in COVID-19; by contrast, therapeutic interventions that target the ...